莱盟健康

Shu Li

President

Dr. Shu Li is an entrepreneur who has successfully founded and accelerated four biotechnology enterprises that have been successfully listed or acquired to date. Dr. Shu Li has been a senior executive of several global top 500 companies, serving as a Senior Vice President of Conexant Systems, Vice President and General Manager of Honeywell Commercial Spares, and has held executive positions at Motorola and Intel.

Bachelor's degree in Automatic Control from Huazhong University of Science and Technology; Master's degree in Electrical Engineering from the University of Illinois Urbana-Champaign; Doctor of Applied Science from Harvard University.

Ze-Yue Zhang

CEO

Mr. Zeyue Zhang is the CEO of LAMH, leading the company to obtain the world's first National Pharmacovigilance Certificate in the field of early liver cancer screening, and becoming the only company to obtain full reimbursement code and pricing from US commercial insurance. Dedicated to the cause of cancer prevention and treatment, he has worked in well-known domestic gene companies such as BGI and CapitalBio MedLab, as well as global pharmaceutical companies such as Eli Lilly, Roche, and Novartis, and also has experience in management of start-up companies, multinational enterprises, well-known private enterprises and state-owned enterprises. He is a recipient of the《Fortune》‘40 under 40 Business Leader’.

Bachelor of Medicine, Southern Medical University; Executive Master of Business Administration (EMBA) from China Europe International Business School (CEIBS).

Yaqing Ding

Group Global Vice President

Ms. Yaqing Ding has strong business strategy and innovation capabilities. She has accumulated rich experience in commercialization and management in the top five multinational pharmaceutical companies and local star Biotech companies around the world. She has full-chain experience in the medical, biotechnology, and gene industries, as well as investment and financing experience, and has a profound understanding and insight into the industry. She has served companies such as AstraZeneca, Novartis, and BeiGene, accumulating rich commercial experience, clinical expertise, and government resources.

EMBA/Master's degree from Cheung Kong Graduate School of Business.

Meng Ding

COO

Ms. Meng Ding has a background in medical and genomic research, and has 12 years of rich work experience in tumor genomics industry research and clinical practice, product and market. She has worked for companies such as BGI, Genetron Health, PLA General Hospital, and Wuxi AppTec, and has held positions such as product director and marketing director.

Bachelor's degree in Natural Science from Peking University Medical School; Master's degree in Molecular Biology from the Chinese Academy of Sciences Institute of Genetics.

Jianfeng Xu

Vice President of Technology

Dr. Jianfeng Xu is a bioinformatics and AI expert. His CHALM methylation algorithm and pan-digestive tract cancer early screening work have been published in Nature Communications and Clinical Cancer Research, respectively.

Bachelor's degree in Life Sciences from Peking University; Ph.D. in Bioinformatics from Baylor College of Medicine.

Sufang Zhang

VP of Registration/Quality

Ms. Zhang Sufang is familiar with Chinese medical device registration regulations and has 12 years of rich registration experience in IVD product registration. Since 2010, Ms. Zhang has been engaged in the registration and declaration of medical devices, and has worked for companies such as Fujirebio, Abbott, Wuxi AppTec, Illumina, and BGI. The products involved include biochemical, immune, blood cell, second-generation sequencing instruments and reagents, PCR products, etc., covering Class I, II, and III products, as well as active devices. She has participated in the formulation and verification of industry standards for testing agencies, including industry standards for prolactin, FSH, T3, rubella virus IgG/IgM test kits, high-throughput sequencers, etc.

Ms. Zhang started her career in medical device registration filing in 2010, and has worked for Fujirebio Corporation, Abbott, WuXi AppTec, Illimina and UW. The products involved are instruments and reagents for biochemistry, immunology, blood cell, and second-generation sequencing, PCR products, etc., covering Class I, II, and III products, as well as active devices. Participated in the development and validation of industry standards for testing organizations, and has participated in industry standards including: kits for lactogen, FSH, T3, rubella virus IgG/IgM, high-throughput sequencers, etc.

Bachelor of Medicine from Sun Yat-sen University School of Public Health; Master's degree in Business Administration from China Agricultural University.

DianGe Li

Director of R&D

Ms. Li Diange is one of the core developers of the "tumor methylation liquid biopsy + multi-omics combined diagnostic products". She has 5 years of experience in basic medical research, tumor early screening and companion diagnostic liquid biopsy product development research and clinical testing experience. She has worked for BGI for nearly 10 years, with experience in high-throughput sequencing technology development, product design, and operation. She led the team to develop and operate multiple clinical scenario detection products and multi-omics detection products for multiple cancers.

Master's degree in Molecular Biology from Nankai University.

Wei Li

Director / Principal Bioinformatics Consultant

Dr. Wei Li is the Director and Chief Bioinformatics Advisor of LAMH. He is a bioinformatics professor at the University of California, Irvine, and has served as a bioinformatics professor at Baylor College of Medicine, where he received the Michael E. DeBakey Excellence in Research Award. Dr. Li has focused on artificial intelligence, bioinformatics big data algorithms, and the application of epigenetics and methylation in cancer research. He has published over 200 articles in international renowned journals, including 23 as corresponding author in Nature, Science, Cell and its sub-journals, with an H-index of 85 and over 54,000 citations.

Dr. Li earned his Ph.D. degree from the Institute of Biophysics, Chinese Academy of Sciences, was a founding member of BGI's bioinformatics team, and completed his postdoctoral research at the Dana-Farber Cancer Institute at Harvard University.